Annex Advisory Services buys $1,537,746 stake in AbbVie Inc (ABBV)

AbbVie Inc (ABBV) : Annex Advisory Services scooped up 1,491 additional shares in AbbVie Inc during the most recent quarter end , the firm said in a disclosure report filed with the SEC on May 2, 2016. The investment management firm now holds a total of 24,600 shares of AbbVie Inc which is valued at $1,537,746.AbbVie Inc makes up approximately 0.44% of Annex Advisory Services’s portfolio.

AbbVie Inc opened for trading at $62 and hit $62.745 on the upside on Friday, eventually ending the session at $62.51, with a gain of 0.27% or 0.17 points. The heightened volatility saw the trading volume jump to 1,08,80,707 shares. Company has a market cap of $100,718 M.

Other Hedge Funds, Including , Spectrum Management Group reduced its stake in ABBV by selling 1,225 shares or 55.61% in the most recent quarter. The Hedge Fund company now holds 978 shares of ABBV which is valued at $59,658. AbbVie Inc makes up approx 0.02% of Spectrum Management Group’s portfolio. American National Bank sold out all of its stake in ABBV during the most recent quarter. The investment firm sold 1 shares of ABBV which is valued $61.Texas Permanent School Fund reduced its stake in ABBV by selling 22,543 shares or 3.9% in the most recent quarter. The Hedge Fund company now holds 556,091 shares of ABBV which is valued at $33,921,551. AbbVie Inc makes up approx 0.43% of Texas Permanent School Fund’s portfolio.

On the company’s financial health, AbbVie Inc reported $1.15 EPS for the quarter, beating the analyst consensus estimate by $ 0.01 according to the earnings call on Apr 28, 2016. Analyst had a consensus of $1.14. The company had revenue of $5958.00 million for the quarter, compared to analysts expectations of $5978.41 million. The company’s revenue was up 18.2% compared to the same quarter last year. During the same quarter in the previous year, the company posted $0.94 EPS.

Many Wall Street Analysts have commented on AbbVie Inc. Societe Generale Initiated AbbVie Inc on Apr 6, 2016 to “Sell”, Price Target of the shares are set at $47.Deutsche Bank Initiated AbbVie Inc on Mar 15, 2016 to “Hold”, Price Target of the shares are set at $63.AbbVie Inc was Upgraded by Citigroup to ” Buy” on Feb 23, 2016.

AbbVie Inc. (AbbVie) is a global research-based biopharmaceutical company. The Company develops and markets therapies that address a range of diseases. The Company’s products are focused on treating conditions such as chronic autoimmune diseases including rheumatoid arthritis psoriasis and Crohn’s disease; hepatitis C (HCV); human immunodeficiency virus (HIV); endometriosis; thyroid disease; Parkinson’s disease; complications associated with chronic kidney disease and cystic fibrosis and other health conditions such as low testosterone. AbbVie also has a pipeline of new medicines including over 30 compounds or indications in Phase II or Phase III development across a range of medical specialties such as immunology virology/liver disease oncology renal disease neurological diseases and women’s health. The Company’s product portfolio includes HUMIRA HCV products Additional Virology products Metabolics/Hormones products Endocrinology products and other products.

Leave a Reply

AbbVie Inc - Is it time to Sell?

Top Brokerage Firms are advising their investors on AbbVie Inc. Subscribe to MoneyFlowIndex.Org Pre-Market Alerts, You will be the first to know the street buzz.